muvalaplin Lp(a)
Selected indexed studies
- Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial. (JAMA, 2025) [PMID:39556768]
- Emerging Lp(a)-Lowering therapies: Is muvalaplin a potential breakthrough? (Int J Cardiol Cardiovasc Risk Prev, 2024) [PMID:39118982]
- Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial. (JAMA, 2023) [PMID:37638695]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Lp(a): A Rapidly Evolving Therapeutic Landscape. (2024) pubmed
- Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial. (2025) pubmed
- Emerging Lp(a)-Lowering therapies: Is muvalaplin a potential breakthrough? (2024) pubmed
- Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial. (2023) pubmed
- Therapeutic Potential of Lipoprotein(a) Inhibitors. (2024) pubmed
- Measuring Lp(a) particles with a novel isoform-insensitive immunoassay illustrates efficacy of muvalaplin. (2025) pubmed
- Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand? (2024) pubmed
- Potential of muvalaplin as a lipoprotein(a) inhibitor. (2024) pubmed
- Discovery of potent small-molecule inhibitors of lipoprotein(a) formation. (2024) pubmed
- Lp(a)-Lowering Agents in Development: A New Era in Tackling the Burden of Cardiovascular Risk? (2025) pubmed